Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Medicinas Complementárias
Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Theranostics ; 11(19): 9311-9330, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34646372

RESUMEN

Aberrant activation of the nucleotide-binding domain and leucine-rich repeat related (NLR) family, pyrin domain containing 3 (NLRP3) inflammasome drives the development of many complex inflammatory diseases, such as obesity, Alzheimer's disease, and atherosclerosis. However, no medications specifically targeting the NLRP3 inflammasome have become clinically available. Therefore, we aim to identify new inhibitors of the NLRP3 inflammasome in this study. Methods: Vesicle-like nanoparticles (VLNs) were extracted from garlic chives and other Allium vegetables and their effects on the NLRP3 inflammasome were evaluated in primary macrophages. After garlic chive-derived VLNs (GC-VLNs) were found to exhibit potent anti-NLRP3 inflammasome activity in cell culture, such function was further assessed in a murine acute liver injury disease model, as well as in diet-induced obesity. Finally, GC-VLNs were subjected to omics analysis to identify the active components with anti-NLRP3 inflammasome function. Results: GC-VLNs are membrane-enclosed nanoparticles containing lipids, proteins, and RNAs. They dose-dependently inhibit pathways downstream of NLRP3 inflammasome activation, including caspase-1 autocleavage, cytokine release, and pyroptotic cell death in primary macrophages. The inhibitory effects of GC-VLNs on the NLRP3 inflammasome are specific, considering their marginal impact on activation of other inflammasomes. Local administration of GC-VLNs in mice alleviates NLRP3 inflammasome-mediated inflammation in chemical-induced acute liver injury. When administered orally or intravenously, GC-VLNs accumulate in specific tissues and suppress activation of the NLRP3 inflammasome and chronic inflammation in diet-induced obese mice. The phospholipid 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC) in GC-VLNs has been identified to inhibit NLRP3 inflammasome activation. Conclusions: Identification of GC-VLNs and their active component DLPC as potent inflammasome inhibitors provides new therapeutic candidates in the treatment of NLRP3 inflammasome-driven diseases.


Asunto(s)
Inflamasomas/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR/efectos de los fármacos , Extractos Vegetales/farmacología , Animales , Antioxidantes/farmacología , China , Cebollino/metabolismo , Citocinas/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Vesículas Extracelulares/metabolismo , Ajo/metabolismo , Inflamación/metabolismo , Mediadores de Inflamación/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Nanopartículas/química , Obesidad , Fagocitosis
2.
Biomedicines ; 9(2)2021 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-33535473

RESUMEN

The nucleotide-binding domain and leucine-rich repeat related (NLR) family, pyrin domain containing 3 (NLRP3) inflammasome is a multimeric protein complex that recognizes various danger or stress signals from pathogens, the host, and the environment, leading to activation of caspase-1 and inducing inflammatory responses. This pro-inflammatory protein complex plays critical roles in pathogenesis of a wide range of diseases including neurodegenerative diseases, autoinflammatory diseases, and metabolic disorders. Therefore, intensive efforts have been devoted to understanding its activation mechanisms and to searching for its specific inhibitors. Approximately forty natural compounds with anti-NLRP3 inflammasome properties have been identified. Here, we provide an update about new natural compounds that have been identified within the last three years to inhibit the NLRP3 inflammasome and offer an overview of the underlying molecular mechanisms of their anti-NLRP3 inflammasome activities.

3.
Nutrients ; 12(2)2020 Feb 13.
Artículo en Inglés | MEDLINE | ID: mdl-32069862

RESUMEN

Fulminant hepatic failure (FHF) is a rare, life-threatening liver disease with a poor prognosis. Administration of D-galactosamine (GalN) and lipopolysaccharide (LPS) triggers acute liver injury in mice, simulating many clinical features of FHF in humans; therefore, this disease model is often used to investigate potential therapeutic interventions to treat FHF. Recently, suppression of the nucleotide-binding domain and leucine-rich repeat related (NLR) family, pyrin domain containing 3 (NLRP3) inflammasome, was shown to alleviate the severity of GalN/LPS-induced liver damage in mice. Therefore, the goal of this study was to find dietary exosome-like nanoparticles (ELNs) with therapeutic potential in curbing FHF by suppressing the NLRP3 inflammasome. Seven commonly consumed mushrooms were used to extract ELNs. These mushrooms were found to contain ELNs composed of RNAs, proteins, and lipids. Among these mushroom-derived ELNs, only shiitake mushroom-derived ELNs (S-ELNs) substantially inhibited NLRP3 inflammasome activation by preventing inflammasome formation in primary macrophages. S-ELNs also suppressed the secretion of interleukin (IL)-6, as well as both protein and mRNA levels of the Il1b gene. Remarkably, pre-treatment with S-ELNs protected mice from GalN/LPS-induced acute liver injury. Therefore, S-ELNs, identified as potent new inhibitors of the NLRP3 inflammasome, represent a promising class of agents with the potential to combat FHF.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Nanopartículas/química , Extractos Vegetales/farmacología , Sustancias Protectoras/farmacología , Hongos Shiitake/química , Animales , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Modelos Animales de Enfermedad , Exosomas , Galactosamina , Lipopolisacáridos , Hígado/metabolismo , Fallo Hepático Agudo/tratamiento farmacológico , Fallo Hepático Agudo/etiología , Macrófagos/efectos de los fármacos , Ratones , Proteína con Dominio Pirina 3 de la Familia NLR/efectos de los fármacos
4.
BMC Genet ; 20(1): 9, 2019 01 14.
Artículo en Inglés | MEDLINE | ID: mdl-30642243

RESUMEN

BACKGROUND: Selenium (Se), an essential micronutrient in both animals and humans, has various biological functions, and its deficiency can lead to various diseases. The most common method for increasing Se uptake is the consumption of Se-rich plants, which transform inorganic Se into organic forms. Wheat is eaten daily by many people. The Se content of Aegilops tauschii (Ae. tauschii), one of the ancestors of hexaploid common wheat, is generally higher than that of wheat. In this study, two genotypes of Ae. tauschii with contrasting Se-accumulating abilities were subjected to different Se treatments followed by high-throughput transcriptome sequencing. RESULTS: Sequencing of 12 transcriptome libraries of Ae. tauschii grown under different Se treatments produced about a total of 47.72 GB of clean reads. After filtering out rRNA sequences, approximately 19.3 million high-quality clean reads were mapped to the reference genome (ta IWGSC_MIPSv2.1 genome DA). The total number of reference genome gene is 32,920 and about 26,407 known genes were detected in four groups. Functional annotation of these mapped genes revealed a large number of genes and some pivotal pathways that may participate in Se metabolism. The expressions of several genes potentially involved in Se metabolism were confirmed by quantitative real-time PCR. CONCLUSIONS: Our study, the first to examine Se metabolism in Ae. tauschii, has provided a theoretical foundation for future elucidation of the mechanism of Se metabolism in this species.


Asunto(s)
Perfilación de la Expresión Génica , Genotipo , Poaceae/efectos de los fármacos , Poaceae/genética , Selenio/metabolismo , Selenio/farmacología , Hojas de la Planta/efectos de los fármacos , Hojas de la Planta/metabolismo , Poaceae/metabolismo , Factores de Transcripción/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA